Option chain shows key data for Sino Biopharmaceutical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Sino Biopharmaceutical.

Sino Biopharmaceutical (OTC:SBMFF) Stock, Option Chain

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Asia

News

Penny Stocks

Markets

General

AAGIY

BABA

CICHY

HNSPF

MPNGY

PNGAY

SBMFF

TCEHY

TSLA

WXXWY

XPEV

NIKE

Hong Kong stocks rallied Friday as the week closed out higher for consumer stocks and EV makers which investors hope will be the beneficiary of a forthcoming government stimulus.  

The Hang Seng Index ended the day 2.1% higher at 17,398.73 while China’s CSI 300 Index rose 1.4% to 3,562.39.

Strong Consumer Turnout Drives Hong Kong Stocks Higher Friday As China&#39;s Former Premier Li Keqiang Dies At 68

Intraday Update

Movers

Trading Ideas

ACKRF

ATUS

AVIFY

BEVVF

BURL

CBLK

CDLX

CLKFF

CLTY

CPRX

CRHKY

DANOY

DKMR

DNACF

New Oriental Education & Technology Group

EMLAF

EPRT

GBBT

GLDLF

GNRC

HEBT

HEI-A

HEMA

HLNE

IDRSF

IMKTA

JBSS

KLAC

KNSL

LAUR

LDOS

LOOP

MAIFF

MEDP

MORN

NSRGF

Nestle Sponsored representing Registered Shares Series B

NSRGY

NXTC

PCTI

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PDRDF

PDRDY

PFSI

RDUS

SHWGY

SSDOY

SSVFF

TCBIP

TERP

TNAV

TORXF

TSGTF

TSPG

WINSTON GOLD MINING ORD by Winston Gold Mining Corp.

WGMCF

XNGSY

XPEL

JMTM

ATBYF

GLGDF

KOOYF

PMMTF

GPPRF

FLMZF

Stocks That Hit 52-Week Highs On Thursday

Biotech

ACAD

ANAB

CELG

GILD

SGMO

4 Biotech Stocks Ready To Crush The Market In 2018

SINO BIOPHARM ORD by Sino Biopharmaceutical Ltd.

Sino Biopharmaceutical Ltd

Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical, through its subsidiary Chia Tai Tianqing, has entered an exclusive...

Sino Biopharmaceutical Signs Key Drug Deal

Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical Limited has announced that its subsidiary, Chia Tai Tianqing Pharma...

Sino Biopharm Advances Share Incentive Scheme

Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical has announced the acceptance of a new drug application for Anlotini...

Sino Biopharmaceutical's New Drug Application Accepted for Advanced Cancer Treatment

Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, has purchased 16.8 million shares ...

Sino Biopharmaceutical's Share Purchase Boosts Incentive Scheme

In a report released on October 25, Chris Lui from Jefferies maintained a Buy rating on Sino Biopharmaceutical (SBMFF – Research Report), with a pr...

Sino Biopharmaceutical (SBMFF) Receives a Buy from Jefferies

Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical reported a robust third quarter in 2024, with a 14.3% increase in r...

Sino Biopharmaceutical Sees Strong Q3 Financial Growth

Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical is making strategic moves to gain control over a target company thr...

Sino Biopharmaceutical to Boost Market Share through Strategic Acquisitions

Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical has received approval to market its KRAS G12C inhibitor, Garsorasib...

Sino Biopharm's Garsorasib Gains Approval in China

Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical has received approval from the U.S. FDA to commence Phase I clinica...

Sino Biopharmaceutical Gains FDA Approval for New Cancer Drug

Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical is set to acquire a 29.99% equity interest in Hob Biotech Group, wi...

Sino Biopharmaceutical's Strategic Investment in Biotech

Sino Biopharmaceutical

Comments

Sino Biopharmaceutical

Sino Biopharmaceutical (SBMFF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga